CHEAR Center LLC | New York, NY

Research site

About

Dr. Bernard Chief Medical Officer: CHEAR Center LLC is a multi-specialty medical clinical trial and research site located at 384 East 149th Street, Suite 205, 2nd Floor, Bronx NY 10455. Phone: 347 270 1111 and 718 600 1679. We conduct research studies on a variety of medical areas and illnesses for all ages. We work with a variety of pharmaceutical companies to develop new treatments and we focus on the participant’s research which may help to improve their overall health.

Location

384 East 149th Street, Suite 205, Bronx, New York, United States of America

Site insights

Top conditions

Top treatments

Vericiguat

Plozasiran

Relamorelin

MK-1242

Ziltivekimab

Rocatinlimab

BLU-5937

MK-1242-035

Gemcabene

Olodaterol

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Jose Garcia, Coordinator

Verified by this site

Active trials

7 of 22 total trials

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling

Heart Failure

Drug: Placebo

Drug: Ziltivekimab

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) (VICTOR)

The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fract...

Active, not recruiting

Chronic Heart Failure With Reduced Ejection Fraction

Drug: Vericiguat

Drug: Placebo

Locations recently updated

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling

Atopic Dermatitis

Drug: Rocatinlimab

Other: Placebo

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1)

This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling

Dermatitis Atopic

Drug: Amlitelimab

Drug: Placebo

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia (MUIR-3)

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). A...

Enrolling

Hypertriglyceridemia

Drug: Placebo

Drug: Plozasiran Injection

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia (SHASTA-3)

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (...

Enrolling

Severe Hypertriglyceridemia

Drug: Plozasiran Injection

Drug: Placebo

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (RENOIR)

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Enrolling

Lower Respiratory Tract Illness

Biological: RSVpreF

Biological: Placebo